Zyprexa/Zyprexa Zydis

Zyprexa/Zyprexa Zydis



Eli Lilly


Concise Prescribing Info
Acute & maintenance treatment of schizophrenia & other psychoses where +ve &/or -ve symptoms are prominent. Alleviates the secondary affective symptoms commonly associated w/ schizophrenia & related disorders. Short-term treatment of acute manic episode associated w/ bipolar I disorder. Prevention of recurrence of manic, mixed or depressive episodes in bipolar I disorder.
Dosage/Direction for Use
Schizophrenia Initially 10 mg/day. Manic episode Initially 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in bipolar disorder Initially 10 mg/day. May subsequently be adjusted w/in the range 5-20 mg daily. Elderly, patient w/ renal &/or hepatic impairment Starting dose: 5 mg/day.
May be taken with or without food: Place orodispersible tab in mouth, it will dissolve rapidly & may be swallowed w/ or w/o water. It may also be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.
Hypersensitivity. Known risk of narrow-angle glaucoma.
Special Precautions
Not to be used for dementia-related psychosis &/or behavioural disturbances or treatment of dopamine agonist associated psychosis in Parkinson's. Discontinue if patient developed signs & symptoms of neuroleptic malignant syndrome (NMS) or presents w/ unexplained high fever w/o additional clinical manifestations of NMS; in cases of hepatitis; acute symptoms (eg, sweating, insomnia, tremor, anxiety, nausea or vomiting). Observe for signs & symptoms of hyperglycaemia. Monitor regularly for worsening of glucose control in patients w/ or w/ risk factors for DM, weight (eg, at baseline, 4, 8 & 12 wk after starting treatment & quarterly thereafter), lipids (eg, at baseline, 12 wk after starting treatment & every 5 yr thereafter). Patients w/ prostatic hypertrophy, or paralytic ileus & related conditions; elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & those treated w/ potentially hepatotoxic drugs; patients w/ low leukocyte &/or neutrophil counts, & in those receiving drugs known to cause neutropenia, history of drug-induced bone marrow depression/toxicity, & in those w/ bone marrow depression caused by concomitant illness, radiation or chemotherapy, hypereosinophilic conditions or w/ myeloproliferative disease, concomitant use w/ valproate; coadministration w/ drugs known to increase QTc interval (especially in elderly), patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalaemia or hypomagnesaemia; coadministration w/ other centrally acting drugs & alcohol; history of seizures, or are subject to factors which may lower seizure threshold. Venous thromboembolism. Discontinue or reduce dose if tardive dyskinesia occurs. Measure BP periodically for patients >65 yr. Sudden cardiac death. Zyprexa contains lactose; not to be taken in patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Zyprexa Zydis contains aspartame (harmful for people w/ phenylketonuria), mannitol, Na methyl parahydroxybenzoate & Na propyl parahydroxybenzoate (known to cause urticaria). May affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescent <18 yr.
Adverse Reactions
Wt gain; somnolence; orthostatic hypotension; elevated plasma prolactin levels. Eosinophilia, leukopenia, neutropenia; elevated cholesterol, glucose & triglyceride levels, glucosuria, increased appetite; dizziness, akathisia, parkinsonism, dyskinesia; mild, transient anticholinergic effects (ie, constipation & dry mouth), transient asymptomatic elevations of hepatic aminotransferases (ALT, AST); rash; arthralgia; erectile dysfunction, decreased libido; asthenia, fatigue, oedema, pyrexia; increased alkaline phosphatase, high creatinine phosphokinase, γ-glutamyltransferase & uric acid.
Drug Interactions
May have induced metabolism w/ carbamazepine & smoking. Inhibited metabolism w/ fluvoxamine, & other CYP1A2 inhibitors (eg, ciprofloxacin, ketoconazole). Reduced bioavailability w/ activated charcoal. May antagonise the effects of direct & indirect dopamine agonists. Alcohol & drugs that may cause CNS depression. Concomitant use w/ anti-Parkinsonian drugs. Drugs known to increase QTc interval.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Zyprexa coated tab 10 mg
Zyprexa coated tab 5 mg
Zyprexa Zydis orodispersible tab 10 mg
Zyprexa Zydis orodispersible tab 5 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in